The influence of herbal medicine on platelet function and coagulation: A narrative review

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 3, 2015, Pages 300-314

  McEwen, Bradley J ^a  

^a Endeavour College of Natural Health   (Australia)

Author keywords

cardiovascular disease; herbal medicine; platelet aggregation; platelet function; warfarin

Indexed keywords

ANTICOAGULANT AGENT; PLANT MEDICINAL PRODUCT;

ANIMAL; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASES; CHEMISTRY; DRUG EFFECTS; DRUG INTERACTION; HUMAN; MALE; MEDICINAL PLANT; MOUSE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAT; THROMBOCYTE;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; HUMANS; MALE; MICE; PLANT PREPARATIONS; PLANTS, MEDICINAL; PLATELET FUNCTION TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS;

EID: 84937760800     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1549089     Document Type: Article

References (109)

1. Go A. S., Mozaffarian D., Roger V. L., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation: 2014; 129 3 e28 e292
2. Ruggeri Z. M. Platelets in atherothrombosis. Nat Med: 2002; 8 11 1227 1234
3. Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J: 1998; 19 (Suppl C): C39 C43
4. Mozaffarian D., Benjamin E. J., Go A. S., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation: 2015; 131 4 e29 e322
5. Lorenzet R., Napoleone E., Cutrone A., Donati M. B. Thrombosis and obesity: cellular bases. Thromb Res: 2012; 129 3 285 289
6. Versteeg H. H., Heemskerk J. W., Levi M., Reitsma P. H. New fundamentals in hemostasis. Physiol Rev: 2013; 93 1 327 358
7. Davì G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med: 2007; 357 24 2482 2494
8. Fontana P., Zufferey A., Daali Y., Reny J. L. Antiplatelet therapy: targeting the TxA2 pathway. J Cardiovasc Transl Res: 2014; 7 1 29 38
9. Furie B., Furie B. C. Mechanisms of thrombus formation. N Engl J Med: 2008; 359 9 938 949
10. Riccioni G., Sblendorio V. Atherosclerosis: from biology to pharmacological treatment. J Geriatr Cardiol: 2012; 9 3 305 317
11. Projahn D., Koenen R. R. Platelets: key players in vascular inflammation. J Leukoc Biol: 2012; 92 6 1167 1175
12. Shantsila E., Lip G. Y. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost: 2009; 102 5 916 924
13. Danese E., Montagnana M., Cervellin G., Lippi G. Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence. Ann Med: 2014; 46 6 364 371
14. Lippi G., Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost: 2008; 34 8 747 761
15. Harrison P., Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin Thromb Hemost: 2009; 35 2 150 157
16. Michelson A. D. Methods for the measurement of platelet function. Am J Cardiol: 2009; 103 (3, Suppl): 20A 26A
17. Born G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature: 1962; 194 927 929
18. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost: 2009; 35 2 158 167
19. Favaloro E. J., Lippi G., Franchini M. Contemporary platelet function testing. Clin Chem Lab Med: 2010; 48 5 579 598
20. Michelson A. D. Flow cytometry: a clinical test of platelet function. Blood: 1996; 87 12 4925 4936
21. Favaloro E. J. Clinical utility of the PFA-100. Semin Thromb Hemost: 2008; 34 8 709 733
22. Patrono C., Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol: 2008; 28 3 s25 s32
23. Morgan G. The established and emerging uses of aspirin. Basic Clin Pharmacol Toxicol: 2006; 99 4 283 286
24. Martínez-Quintana E., Tugores A. Clopidogrel: a multifaceted affair. J Clin Pharmacol: 2015; 55 1 1 9
25. Karaźniewicz-Łada M., Danielak D., Burchardt P., et al. Clinical pharmacokinetics of clopidogrel and its metabolites in patients with cardiovascular diseases. Clin Pharmacokinet: 2014; 53 2 155 164
26. Wadhera R. K., Russell C. E., Piazza G. Cardiology patient page. Warfarin versus novel oral anticoagulants: how to choose? Circulation: 2014; 130 22 e191 e193
27. Hamann G. L., Campbell J. D., George C. M. Warfarin-cranberry juice interaction. Ann Pharmacother: 2011; 45 3 e17
28. Winslow L. C., Kroll D. J. Herbs as medicines. Arch Intern Med: 1998; 158 20 2192 2199
29. Mashour N. H., Lin G. I., Frishman W. H. Herbal medicine for the treatment of cardiovascular disease: clinical considerations. Arch Intern Med: 1998; 158 20 2225 2234
30. McEwen B. J. The influence of diet and nutrients on platelet function. Semin Thromb Hemost: 2014; 40 2 214 226
31. Lu W. J., Lin K. H., Hsu M. J., Chou D. S., Hsiao G., Sheu J. R. Suppression of NF-κB signaling by andrographolide with a novel mechanism in human platelets: regulatory roles of the p38 MAPK-hydroxyl radical-ERK2 cascade. Biochem Pharmacol: 2012; 84 7 914 924
32. Thisoda P., Rangkadilok N., Pholphana N., Worasuttayangkurn L., Ruchirawat S., Satayavivad J. Inhibitory effect of Andrographis paniculata extract and its active diterpenoids on platelet aggregation. Eur J Pharmacol: 2006; 553 1-3 39 45
33. Amroyan E., Gabrielian E., Panossian A., Wikman G., Wagner H. Inhibitory effect of andrographolide from Andrographis paniculata on PAF-induced platelet aggregation. Phytomedicine: 1999; 6 1 27 31
34. Mohammed Abdul M. I., Jiang X., Williams K. M., et al. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol: 2008; 154 8 1691 1700
35. Zhou L., Wang S., Zhang Z., et al. Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin. J Ethnopharmacol: 2012; 143 2 648 655
36. Chan K., Lo A. C., Yeung J. H., Woo K. S. The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol: 1995; 47 5 402 406
37. Dong W. G., Liu S. P., Zhu H. H., Luo H. S., Yu J. P. Abnormal function of platelets and role of angelica sinensis in patients with ulcerative colitis. World J Gastroenterol: 2004; 10 4 606 609
38. Page R. L. II, Lawrence J. D. Potentiation of warfarin by dong quai. Pharmacotherapy: 1999; 19 7 870 876
39. Groenewegen W. A., Heptinstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro. J Pharm Pharmacol: 1990; 42 8 553 557
40. Biggs M. J., Johnson E. S., Persaud N. P., Ratcliffe D. M. Platelet aggregation in patients using feverfew for migraine. Lancet: 1982; 2 8301 776
41. Sahler J., Bernard J. J., Spinelli S. L., Blumberg N., Phipps R. P. The feverfew plant-derived compound, parthenolide enhances platelet production and attenuates platelet activation through NF-κB inhibition. Thromb Res: 2011; 127 5 426 434
42. Bordia A., Verma S. K., Srivastava K. C. Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids: 1996; 55 3 201 205
43. Rahman K., Billington D. Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans. J Nutr: 2000; 130 11 2662 2665
44. Allison G. L., Lowe G. M., Rahman K. Aged garlic extract may inhibit aggregation in human platelets by suppressing calcium mobilization. J Nutr: 2006; 136 (3, Suppl): 789S 792S
45. Steiner M., Lin R. S. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. J Cardiovasc Pharmacol: 1998; 31 6 904 908
46. Wojcikowski K., Myers S., Brooks L. Effects of garlic oil on platelet aggregation: a double-blind placebo-controlled crossover study. Platelets: 2007; 18 1 29 34
47. Bordia A., Verma S. K., Srivastava K. C. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids: 1997; 56 5 379 384
48. Nurtjahja-Tjendraputra E., Ammit A. J., Roufogalis B. D., Tran V. H., Duke C. C. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thromb Res: 2003; 111 4-5 259 265
49. Lamant V., Mauco G., Braquet P., Chap H., Douste-Blazy L. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba. Biochem Pharmacol: 1987; 36 17 2749 2752
50. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine: 2005; 12 1-2 10 16
51. Jin Y. R., Yu J. Y., Lee J. J., et al. Antithrombotic and antiplatelet activities of Korean red ginseng extract. Basic Clin Pharmacol Toxicol: 2007; 100 3 170 175
52. Lee S. H., Ahn Y. M., Ahn S. Y., Doo H. K., Lee B. C. Interaction between warfarin and Panax ginseng in ischemic stroke patients. J Altern Complement Med: 2008; 14 6 715 721
53. Yuan C. S., Wei G., Dey L., et al. Brief communication: American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med: 2004; 141 1 23 27
54. Zhou Q., Jiang L., Xu C., et al. Ginsenoside Rg1 inhibits platelet activation and arterial thrombosis. Thromb Res: 2014; 133 1 57 65
55. Lau A. J., Toh D. F., Chua T. K., Pang Y. K., Woo S. O., Koh H. L. Antiplatelet and anticoagulant effects of Panax notoginseng: comparison of raw and steamed Panax notoginseng with Panax ginseng and Panax quinquefolium. J Ethnopharmacol: 2009; 125 3 380 386
56. Iida Y., Doi T., Matsushima-Nishiwaki R., et al. (-)-Epigallocatechin gallate selectively inhibits adenosine diphosphate stimulated human platelet activation: suppression of heat shock protein 27 phosphorylation via p38 mitogen activated protein kinase. Mol Med Rep: 2014; 10 3 1383 1388
57. Son D. J., Cho M. R., Jin Y. R., et al. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostaglandins Leukot Essent Fatty Acids: 2004; 71 1 25 31
58. Rogers K. L., Grice I. D., Griffiths L. R. Inhibition of platelet aggregation and 5-HT release by extracts of Australian plants used traditionally as headache treatments. Eur J Pharm Sci: 2000; 9 4 355 363
59. Vibes J., Lasserre B., Gleye J., Declume C. Inhibition of thromboxane A2 biosynthesis in vitro by the main components of Crataegus oxyacantha (hawthorn) flower heads. Prostaglandins Leukot Essent Fatty Acids: 1994; 50 4 173 175
60. Xiong L., Zhou Q. M., Peng C., et al. Bis-spirolabdane diterpenoids from Leonurus japonicus and their anti-platelet aggregative activity. Fitoterapia: 2015; 100 1 6
61. Xiong L., Zhou Q. M., Peng C., et al. Sesquiterpenoids from the herb of Leonurus japonicus. Molecules: 2013; 18 5 5051 5058
62. Lau W. C., Welch T. D., Shields T., Rubenfire M., Tantry U. S., Gurbel P. A. The effect of St John's wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. J Cardiovasc Pharmacol: 2011; 57 1 86 93
63. Yue Q. Y., Bergquist C., Gerdén B. Safety of St John's wort (Hypericum perforatum). Lancet: 2000; 355 9203 576 577
64. Shah B. H., Nawaz Z., Pertani S. A., et al. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca2+ signaling. Biochem Pharmacol: 1999; 58 7 1167 1172
65. Srivastava K. C., Bordia A., Verma S. K. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot Essent Fatty Acids: 1995; 52 4 223 227
66. Mayanglambam A., Dangelmaier C. A., Thomas D., Damodar Reddy C., Daniel J. L., Kunapuli S. P. Curcumin inhibits GPVI-mediated platelet activation by interfering with the kinase activity of Syk and the subsequent activation of PLCgamma2. Platelets: 2010; 21 3 211 220
67. Krivoy N., Pavlotzky E., Chrubasik S., Eisenberg E., Brook G. Effect of salicis cortex extract on human platelet aggregation. Planta Med: 2001; 67 3 209 212
68. Craig W. J. Health-promoting properties of common herbs. Am J Clin Nutr: 1999; 70 (3, Suppl): 491S 499S
69. Vickers A., Zollman C. ABC of complementary medicine: herbal medicine. BMJ: 1999; 319 7216 1050 1053
70. Yeh G. Y., Davis R. B., Phillips R. S. Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol: 2006; 98 5 673 680
71. Wood M. J., Stewart R. L., Merry H., Johnstone D. E., Cox J. L. Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J: 2003; 145 5 806 812
72. Chen X. W., Sneed K. B., Pan S. Y., et al. Herb-drug interactions and mechanistic and clinical considerations. Curr Drug Metab: 2012; 13 5 640 651
73. Blumberg J. B., Camesano T. A., Cassidy A., et al. Cranberries and their bioactive constituents in human health. Adv Nutr: 2013; 4 6 618 632
74. McKay D. L., Blumberg J. B. Cranberries (Vaccinium macrocarpon) and cardiovascular disease risk factors. Nutr Rev: 2007; 65 11 490 502
75. Mellen C. K., Ford M., Rindone J. P. Effect of high-dose cranberry juice on the pharmacodynamics of warfarin in patients. Br J Clin Pharmacol: 2010; 70 1 139 142
76. Yu C. M., Chan J. C., Sanderson J. E. Chinese herbs and warfarin potentiation by 'danshen' J Intern Med: 1997; 241 4 337 339
77. Cheng T. O. Cardiovascular effects of Danshen. Int J Cardiol: 2007; 121 1 9 22
78. Izzat M. B., Yim A. P., El-Zufari M. H. A taste of Chinese medicine! Ann Thorac Surg: 1998; 66 3 941 942
79. Pareek A., Suthar M., Rathore G. S., Bansal V. Feverfew (Tanacetum parthenium L.): a systematic review. Pharmacogn Rev: 2011; 5 9 103 110
80. Khatua T. N., Adela R., Banerjee S. K. Garlic and cardioprotection: insights into the molecular mechanisms. Can J Physiol Pharmacol: 2013; 91 6 448 458
81. Rahman K., Lowe G. M. Garlic and cardiovascular disease: a critical review. J Nutr: 2006; 136 (3, Suppl): 736S 740S
82. Foster B. C., Foster M. S., Vandenhoek S., et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci: 2001; 4 2 176 184
83. Bartels E. M., Folmer V. N., Bliddal H., et al. Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage: 2015; 23 1 13 21
84. Jiang X., Williams K. M., Liauw W. S., et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol: 2005; 59 4 425 432
85. Heinonen T., Gaus W. Cross matching observations on toxicological and clinical data for the assessment of tolerability and safety of Ginkgo biloba leaf extract. Toxicology: 2015; 327C 95 115
86. Kudolo G. B., Dorsey S., Blodgett J. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. Thromb Res: 2002; 108 2-3 151 160
87. Jung F., Mrowietz C., Kiesewetter H., Wenzel E. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung: 1990; 40 5 589 593
88. Gardner C. D., Zehnder J. L., Rigby A. J., Nicholus J. R., Farquhar J. W. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagul Fibrinolysis: 2007; 18 8 787 793
89. Lee C. H., Kim J. H. A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. J Ginseng Res: 2014; 38 3 161 166
90. Thielecke F., Boschmann M. The potential role of green tea catechins in the prevention of the metabolic syndrome - a review. Phytochemistry: 2009; 70 1 11 24
91. Yousaf S., Butt M. S., Suleria H. A., Iqbal M. J. The role of green tea extract and powder in mitigating metabolic syndromes with special reference to hyperglycemia and hypercholesterolemia. Food Funct: 2014; 5 3 545 556
92. Cheng T. O. Green tea may inhibit warfarin. Int J Cardiol: 2007; 115 2 236
93. Wang J., Xiong X., Feng B. Effect of Crataegus usage in cardiovascular disease prevention: an evidence-based approach. Evid Based Complement Alternat Med: 2013; 2013 149363
94. Brenyo A., Aktas M. K. Review of complementary and alternative medical treatment of arrhythmias. Am J Cardiol: 2014; 113 5 897 903
95. Felixsson E., Persson I. A., Eriksson A. C., Persson K. Horse chestnut extract contracts bovine vessels and affects human platelet aggregation through 5-HT(2A) receptors: an in vitro study. Phytother Res: 2010; 24 9 1297 1301
96. Pittler M. H., Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev: 2012; 11 CD003230
97. Sirtori C. R. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res: 2001; 44 3 183 193
98. Shang X., Pan H., Wang X., He H., Li M. Leonurus japonicus Houtt.: ethnopharmacology, phytochemistry and pharmacology of an important traditional Chinese medicine. J Ethnopharmacol: 2014; 152 1 14 32
99. Zou Q. Z., Bi R. G., Li J. M., et al. Effect of motherwort on blood hyperviscosity. Am J Chin Med: 1989; 17 1-2 65 70
100. Russo E., Scicchitano F., Whalley B. J., et al. Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions. Phytother Res: 2014; 28 5 643 655
101. Obach R. S. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther: 2000; 294 1 88 95
102. Prasad S., Gupta S. C., Tyagi A. K., Aggarwal B. B. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv: 2014; 32 6 1053 1064
103. Aggarwal B. B., Sundaram C., Malani N., Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol: 2007; 595 1 75
104. Hatcher H., Planalp R., Cho J., Torti F. M., Torti S. V. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci: 2008; 65 11 1631 1652
105. Menon V. P., Sudheer A. R. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol: 2007; 595 105 125
106. Schmid B., Lüdtke R., Selbmann H. K., et al. Efficacy and tolerability of a standardized willow bark extract in patients with osteoarthritis: randomized placebo-controlled, double blind clinical trial. Phytother Res: 2001; 15 4 344 350
107. Vainio H., Morgan G. Aspirin for the second hundred years: new uses for an old drug. Pharmacol Toxicol: 1997; 81 4 151 152
108. Lippi G., Favaloro E. J. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med: 2015; 53 2 185 197
109. Lippi G., Favaloro E. J., Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? Semin Thromb Hemost: 2014; 40 7 756 765